-

Personal Genomics Pioneer George Church, PhD, to Keynote PEGS: The Essential Protein Engineering & Cell Therapy Summit

More than 2,800 Scientists and Innovators Focused on Blockbuster Biologics to Meet May 4-8 in Boston

BOSTON--(BUSINESS WIRE)--Cambridge Healthtech Institute (CHI) announces that George M. Church, PhD, whose innovations have been seminal to precision medicine, will serve as a Plenary Keynote at PEGS: The Essential Protein Engineering & Cell Therapy Summit, May 4-8, 2020 at the Seaport World Trade Center, Boston.

The conference will unite 2,800 experts from pharmaceutical and biotech organizations, government and academia focused on developing the next blockbuster biologics, including immunotherapies, gene and cell therapies, bispecific antibodies, antibody-drug conjugates, and more.

“We are thrilled that George Church, who has had a profound influence on biotherapeutics, will share his perspective on the transformations and opportunities ahead,” said Christina (Tina) Lingham, Executive Director, Conferences and Fellow, CHI.

Dr. Church, Professor of Genetics at Harvard Medical School, is known for pioneering personal genomics and synthetic biology, and developing the first methods for the first genome sequence.

His presentation, “From Energy to Machine Learning,” will focus on new frontiers in protein design that deep learning and machine learning will make possible. He will be followed by Young Scientist Keynote Jamie Spangler, PhD, Assistant Professor, Biomedical Engineering and Chemical & Biomolecular Engineering, Johns Hopkins University, addressing “The Case for Intelligent Design in Protein Engineering.”

Altogether, PEGS will feature more than 350 presenters on engineering, oncology, immunotherapy, cell-based immunotherapies, analytical, expression, immunogenicity & bioassays, bioconjugates, and emerging therapeutics and technologies. Other highlights include 170+ Exhibitors, a Women in Science panel, Breakout Discussions, Short Courses, Training Seminars, Poster Sessions and One-on-One Networking.

See PEGSummit.com.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, World Pharma Week, The Bioprocessing Summit, Next Generation Dx Summit, Immuno-Oncology Summit, and Discovery on Target. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Bio-IT World, Clinical Research News and Diagnostics World.

Contacts

Nicole Proulx
+1-781-972-5417
nproulx@healthtech.com

Cambridge Healthtech Institute


Release Summary
Personal genomics pioneer George Church, PhD, will keynote PEGS: The Essential Protein Engineering & Cell Therapy Summit, May 4-8, 2020 in Boston.
Release Versions

Contacts

Nicole Proulx
+1-781-972-5417
nproulx@healthtech.com

Social Media Profiles
More News From Cambridge Healthtech Institute

From Ending Addiction to Preventive Genomics, Bio-IT World 2020 Keynoters Share Data-Driven Approaches

BOSTON--(BUSINESS WIRE)--From data strategies to combat addiction, to preventive genomics, Bio-IT World 2020 keynotes will explore tech catalyzing breakthroughs....

Bioprocessing Summit Europe Highlights Innovations in Gene Therapy CMC and Manufacturing

BARCELONA, Spain--(BUSINESS WIRE)--Gene Therapy CMC and Manufacturing will be a focal point of Bioprocessing Summit Europe, March 24-26, 2020 in Barcelona....

Precision Medicine Leaps Ahead with Data Science: Bio-IT World 2020 to Highlight Data-Driven Approaches to Discovery

BOSTON--(BUSINESS WIRE)--Bio-IT World 2020, uniting 3,200+ participants in Boston April 21-23, 2020, will feature an expanded focus on innovating with Data Science....
Back to Newsroom